摘要
目的探讨替罗非班在易化PCI治疗急性心肌梗死中的有效性和安全性。方法将89例急性心肌梗死患者按治疗方法不同分为治疗组45例(应用替罗非班联合溶栓剂的易化PCI治疗)、对照组44例(应用常规溶栓剂的易化PCI治疗)。比较2组的临床疗效与安全性。结果 2组溶栓治疗时间比较差异无统计学意义(P>0.05)。对照组有2例术后7 d发生再梗死,其中1例在再次干预后死亡,治疗组无死亡病例。治疗组术后TIMI计帧数、90 min ST段下降幅度均明显高于对照组(P<0.05),肌酸激酶峰值明显低于对照组(P<0.05);其余观察指标(TIMI 3级血流获得率、左心室射血分数、并发症及住院时间、费用)2组相比差异均无统计学意义(P>0.05)。结论应用替罗非班易化PCI治疗急性心肌梗死安全、有效,值得临床推广应用。
Objective To investigate the efficacy and safety of tirofiban in the treatment of acute myocardial infarction with facilitated PCI. Methods A total of 89 patients with acute myocardial infarction were treated with thrombolytic therapy-facilitated PCI alone （control group,n=44）or in comb- ination with tirofiban （treatment group,n=45）. The efficacy and safety were compared between the two groups. Results There was no significant difference in the duration of thrombolytic treatment between the two groups （P＇M3.05）.In control group,2 patients had reinfarction 7 days after operation and one of the two patients died after the second intervention. No death occurred in treatment＇ group. Compared with control group, TIMI frame count and ST segment decline at 90 minutes significantly increased but creatine kinase peak significantly decreased in treatment group（P〈0.05）.No obvious differences in TIMI 3 flow rate, left ventricular ejection fraction, complications, hospital stay and costs were found between the two groups（P〉0.05）.Conclusion Tirofiban-facilitated PCI is safe and effective for acute myocardial infarction. It is worthy of clinical application.
出处
《实用临床医学（江西）》
CAS
2013年第6期26-28,共3页
Practical Clinical Medicine
